Needham Reiterates Buy on KalVista Pharma, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on KalVista Pharmaceuticals (KALV) and maintained a $35 price target.

April 11, 2024 | 10:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham maintains a Buy rating and a $35 price target on KalVista Pharmaceuticals.
The reiteration of a Buy rating and maintenance of a $35 price target by a reputable analyst firm like Needham is likely to instill confidence among investors and could lead to a positive short-term impact on KALV's stock price. Analyst ratings and price targets are significant indicators for investors, and positive reaffirmations can drive investor sentiment and stock performance.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100